The global marketplace for Gram-negative bacteria was valued 2.43 Billion in 2019 and is projected to exceed $xx billion by 2028, at a Compound Annual Growth Rate (CAGR) of 10.8% from 2019–2028.
According to the list made public by the WHO, among the various MDR Gram-negative bacterial organisms, few that pose significant remerging threats and are of high priority include Pseudomonas aeruginosa, Acinetobacter Baumann, Enterobacteriaceae, Enterococcus faecium, Helicobacter pylori, Helicobacter pylori, Neisseria gonorrhoeae. Most of these are associated with causing urinary tract infections, nosocomial infections, and pneumonia. The mounting burden of these infections on public health, especially in emerging nations, is attributed to the rate of antibiotic resistance growing at a faster pace than the pace at which new drugs are being developed Hence, it becomes all the more mandatory that pharmaceutical companies and drug makers to actively focus on expanding the armory of novel therapeutics and accelerate clinical researches in the coming years
Market Growth Drivers
The rising prevalence of various rare diseases globally is expected to support the criteria of the hospital-treated gram-negative infections market. There has been a rising need for newer drugs for getting the appropriate effect on the micro-organisms. The increasing number of strains of the bacteria and growing resistance towards the previously existing pathogens are expected to favor the market for drugs used in hospital-treated gram-negative infections. The world is running out of drugs for infections caused due to gram-negative bacteria. However, companies are laying efforts in drug discoveries by spending more and more on research and development. Furthermore, among all of the bacterial resistance problems, gram-negative pathogens are particularly troublesome and a reason for a major worry in the physician community as they are getting resistant to the maximum currently available drugs. The most common gram-negative infections include the pathogens such as Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter. Major challenges are rising for the treatment of patient suffering from pan-resistant or nearly pan-resistant gram-negative microorganisms